Post-Discharge Outcomes of Elderly Patients Hospitalized for Inflammatory Bowel Disease Flare Complicated by Clostridioides difficile Infection - Summary - MDSpire

Post-Discharge Outcomes of Elderly Patients Hospitalized for Inflammatory Bowel Disease Flare Complicated by Clostridioides difficile Infection

  • By

  • Idan Goren

  • Ortal Fallek Boldes

  • Tomer Boldes

  • Oleg Knyazev

  • Anna Kagramanova

  • Jimmy K Limdi

  • Eleanor Liu

  • Karishma Sethi-Arora

  • Tom Holvoet

  • Piotr Eder

  • Cristina Bezzio

  • Simone Saibeni

  • Marta Vernero

  • Eleonora Alimenti

  • María Chaparro

  • Javier P Gisbert

  • Eleni Orfanoudaki

  • Ioannis E Koutroubakis

  • Daniela Pugliese

  • Giuseppe Cuccia

  • Cristina Calviño Suarez

  • Davide Giuseppe Ribaldone

  • Ido Veisman

  • Kassem Sharif

  • Stefano Festa

  • Annalisa Aratari

  • Claudio Papi

  • Iordanis Mylonas

  • Gerassimos J Mantzaris

  • Marie Truyens

  • Triana Lobaton Ortega

  • Stéphane Nancey

  • Fabiana Castiglione

  • Olga Maria Nardone

  • Giulio Calabrese

  • Konstantinos Karmiris

  • Magdalini Velegraki

  • Angeliki Theodoropoulou

  • Ariella Bar-Gil Shitrit

  • Milan Lukas

  • Gabriela Vojtechová

  • Pierre Ellul

  • Luke Bugeja

  • Edoardo V Savarino

  • Tali Sharar Fischler

  • Iris Dotan

  • Henit Yanai

  • October 21, 2024

  • 0 min

Share

Objective:

To evaluate post-discharge complications in elderly patients with inflammatory bowel disease (IBD) flare and concurrent Clostridioides difficile infection (CDI), highlighting the significance of understanding these outcomes for better patient management.

Key Findings:
  • Post-discharge complication rates at 3 months were 32% for CDI-positive and 33.1% for CDI-negative patients (p = 0.8), indicating no significant difference.
  • At 6 months, complication rates were 40.5% for CDI-positive and 42.5% for CDI-negative (p = 0.66), suggesting similar outcomes.
  • 12-month mortality was 4.6% for CDI-positive and 8% for CDI-negative (p = 0.153), with no significant impact from CDI.
  • Charlson comorbidity index was a significant risk factor for complications within 3 months (aOR 1.1), while mesalamine use was protective against complications (aOR 0.6).
Interpretation:

Concurrent CDI infection did not significantly impact post-discharge IBD-related complications or mortality in elderly patients, suggesting that management strategies may not need to change based on CDI status alone.

Limitations:
  • Retrospective design may introduce bias, and potential confounding factors were not fully controlled for.
  • Single hospitalization data included for patients with multiple admissions, which may not represent their overall risk.
Conclusion:

In elderly IBD patients hospitalized for flare, concurrent CDI infection is not associated with increased post-discharge complications or mortality up to 1 year, underscoring the need for tailored care strategies.

Original Source(s)

Post-Discharge Outcomes of Elderly Patients Hospitalized for Inflammatory Bowel Disease Flare Complicated by Clostridioides difficile Infection

  • by Idan Goren, Ortal Fallek Boldes, Tomer Boldes, Oleg Knyazev, Anna Kagramanova, Jimmy K Limdi, Eleanor Liu, Karishma Sethi-Arora, Tom Holvoet, Piotr Eder, Cristina Bezzio, Simone Saibeni, Marta Vernero, Eleonora Alimenti, María Chaparro, Javier P Gisbert, Eleni Orfanoudaki, Ioannis E Koutroubakis, Daniela Pugliese, Giuseppe Cuccia, Cristina Calviño Suarez, Davide Giuseppe Ribaldone, Ido Veisman, Kassem Sharif, Stefano Festa, Annalisa Aratari, Claudio Papi, Iordanis Mylonas, Gerassimos J Mantzaris, Marie Truyens, Triana Lobaton Ortega, Stéphane Nancey, Fabiana Castiglione, Olga Maria Nardone, Giulio Calabrese, Konstantinos Karmiris, Magdalini Velegraki, Angeliki Theodoropoulou, Ariella Bar-Gil Shitrit, Milan Lukas, Gabriela Vojtechová, Pierre Ellul, Luke Bugeja, Edoardo V Savarino, Tali Sharar Fischler, Iris Dotan, Henit Yanai

  • October 21, 2024

Related Content

Evaluation of Tacrolimus in Ulcerative Colitis: A Retrospective Analysis of Factors Influencing Remission Induction and Maintenance

Ethosuximide vs Placebo for IBS Pain

Randomized trial found no improvement in abdominal pain and higher discontinuation rates with the calcium channel blocker.

Side Effects: Four Studies Worth Passing On

Kissing celiacs, Ozempic genes, Viagra for the brain, and a UTI test that actually works. This week's evidence is weird, useful, and worth your time.